(Q39925612)

English

The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs

scientific article published on October 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs (English)

1 reference

Europe PubMed Central

15 September 2017

1 reference

based on heuristic

inferred from title

author name string

Mario I Vega

1

1 reference

Europe PubMed Central

15 September 2017

Melissa Martinez-Paniagua

2

1 reference

Europe PubMed Central

15 September 2017

Ali R Jazirehi

3

1 reference

Europe PubMed Central

15 September 2017

Sara Huerta-Yepez

4

1 reference

Europe PubMed Central

15 September 2017

Kazuo Umezawa

5

1 reference

Europe PubMed Central

15 September 2017

Otoniel Martinez-Maza

6

1 reference

Europe PubMed Central

15 September 2017

Benjamin Bonavida

7

1 reference

Europe PubMed Central

15 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2008

1 reference

Europe PubMed Central

15 September 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

15 September 2017

49

1 reference

Europe PubMed Central

15 September 2017

10

1 reference

Europe PubMed Central

15 September 2017

1982-1994

1 reference

Europe PubMed Central

15 September 2017

Monoclonal antibody therapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Modern management of non-Hodgkin lymphoma in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Update on HIV lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Advances in the management of HIV-related non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Rituximab for HIV-associated lymphoma: weighing the benefits and risks.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Inhibition of tumor growth by NF-kappaB inhibitors

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

CD20-mediated apoptosis: signalling through lipid rafts

1 reference

https://api.crossref.org/works/10.1080%2F10428190802357071

21 January 2018

Identifiers

10.1080/10428190802357071

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39925612&oldid=1878694794"